She Found a Breast Lump at 26 With No Known Family History
Guest Contributor
When a 26-year-old woman finds a breast lump, the first reaction is often disbelief. Breast cancer is still widely seen as something that happens later in life. Yet the story of Andrea de Armas, highlighted by CBS News and Baptist Health, shows that young-onset breast cancer and inherited gene mutations such as PALB2 can appear even when there is no known family history. Her experience underscores an important message for young women and their families: a new breast lump deserves timely evaluation at any age.
Andrea was preparing to begin physician assistant school when she felt a small, painless lump in her breast while showering. She had no known family history of breast cancer and no reason to suspect a serious diagnosis. Still, she sought medical attention. According to the account, she described how her concerns initially felt brushed aside until a radiologist carefully reviewing her ultrasound recommended an immediate biopsy. That step changed everything. The biopsy revealed invasive ductal carcinoma, a type of breast cancer, and further evaluation found that the cancer had already spread to several lymph nodes.
This fast-moving diagnosis came just as her life was about to accelerate in another direction. She had additional imaging and a biopsy at Baptist Health’s Miami Cancer Institute, now the Herbert Wertheim Cancer Institute. Four days later, the day before her program started, she received confirmation of breast cancer. The tumor was hormone receptor positive, which shaped how her care team designed her treatment plan. Her cancer care unfolded in parallel with the demands of graduate school, a dual journey that required meticulous coordination.
To accommodate her education, her clinicians helped map treatment around academic breaks and class schedules. She underwent a lumpectomy in June 2023 while on a school break. Chemotherapy followed, scheduled in early morning sessions so she could still attend afternoon classes. Later that year, she had a double mastectomy with reconstruction during her December break. Because her lymph nodes were involved, radiation therapy was also included in her plan. Throughout all of this, she was not simply a patient but also a student, moving between infusion chairs and classrooms.
Hormone-positive breast cancer in young women brings its own set of long-term decisions. Andrea began hormone therapy that combined an oral medication with monthly injections to suppress ovarian estrogen production. This approach, as her surgeon Dr. Cristina Lopez-Penalver explained, can place women in a temporary menopause and is often continued for five to ten years. That timeline has major implications for fertility, quality of life, and future family planning. Andrea’s team discussed fertility preservation with her before treatment progressed, a conversation they recommend for all patients of childbearing age who face similar therapies.
Lopez-Penalver emphasized that breast cancer care is not a one-size-fits-all process. Instead it is tailored to each person’s life stage, goals, tumor biology, and genetic findings. Andrea’s case illustrates this clearly. In 2025, she completed her physician assistant training and now reports that she is cancer free. She continues with regular follow-up care, reflecting the reality that survivorship is a long-term phase of cancer care, not simply an endpoint.
One of the most significant elements of her story involves the PALB2 gene. After her diagnosis, genetic testing revealed that she carries an inherited PALB2 mutation. According to the National Cancer Institute, PALB2 works with the more widely known BRCA1 and BRCA2 genes to help repair damaged DNA. Harmful changes in PALB2 increase the lifetime risk of breast cancer and also raise the risk of pancreatic and ovarian cancer. Lopez-Penalver noted that PALB2 mutations can increase prostate cancer risk in men, although the National Cancer Institute reports that this particular link is not yet fully confirmed. Importantly, a PALB2 mutation can be inherited even when there is no obvious family history of cancer, which means a negative family history does not guarantee a negative genetic test.
Breast cancer in women in their 20s remains uncommon. American Cancer Society figures cited in the coverage estimate that about 1 in 1,344 women will be diagnosed in their 20s. Approximately 1 in 10 new breast cancer cases occur in women younger than 45. Over recent years, overall breast cancer incidence has increased at about 1 percent annually and at about 1.4 percent each year in women under 50. While those percentages may sound modest, they translate into meaningful numbers of people, many of them in the midst of education, early careers, or starting families.
Young women are more likely to receive a diagnosis at a later stage. This trend is partly due to screening guidelines, since routine mammograms for women at average risk usually begin at age 40. Dr. Mary Gemignani, who directs the Women’s Early Onset Cancer Program at NYU Langone and was not involved in Andrea’s care, told CBS that young women tend to have more aggressive tumors. This combination of later-stage detection and more aggressive biology helps explain why prompt evaluation of any breast change is so important, regardless of age.
One person’s story cannot answer how common PALB2 mutations are among young patients or predict the trajectory of any individual’s illness. What it does show is that a single genetic test result can reshape care not only for the patient but for relatives as well. When someone tests positive for a mutation such as PALB2, close family members can undergo targeted genetic testing. Those who also carry the mutation can work with their clinicians to plan earlier or more frequent screening and discuss risk-reducing strategies. I found this detail striking because it highlights how one diagnosis often initiates a broader family conversation about health, risk, and prevention.
Andrea’s experience also illustrates which symptoms should prompt evaluation. Clinicians recommend having breast changes assessed if there is a new lump or area of thickening, a change in breast size or shape, skin dimpling or redness, nipple changes or discharge, or swelling in the armpit. In younger women, most lumps turn out to be benign conditions such as cysts or fibroadenomas. Even so, a lump that persists or grows should not be ignored. If someone feels that their concern is being dismissed, it can be appropriate to ask for imaging, a referral to a breast specialist, or a second opinion. Asking what would confidently rule out cancer can help clarify the next diagnostic step.
Genetic counseling is another key part of the conversation about early-onset breast cancer and inherited risk. Counseling may be especially relevant for individuals diagnosed with breast cancer at a young age, those with relatives who had breast, ovarian, pancreatic, or prostate cancer, and those with Ashkenazi Jewish ancestry. The American Cancer Society notes that PALB2 is among the genes linked to inherited breast cancer risk, alongside BRCA1 and BRCA2. A genetic counselor can explain which tests are appropriate, what results may mean, and how they might influence screening or treatment plans.
Cost is a real concern for many people when considering both imaging and genetic testing. The article notes that many insurance plans cover genetic testing when individuals meet established guidelines. For those who are not eligible under standard criteria, genetic counselors can often suggest lower cost self-pay options. Similarly, free or low-cost breast exams and imaging are available in many areas through state and local programs for uninsured women. These resources are not always widely known, yet they can make the difference between postponing evaluation and getting timely answers.
Young survivors like Andrea face particular challenges that go beyond the physical effects of treatment. Fertility planning, early menopause, body image changes, and the emotional impact of navigating a life-threatening illness alongside school or work can all be profound. Discussing fertility preservation before treatment starts provides the greatest number of options, including egg or embryo freezing and other approaches that might be suitable depending on timing and diagnosis. These are deeply personal choices, but they are easier to consider when they are presented early and clearly.
Ultimately, Andrea’s experience carries several interconnected lessons. A new breast lump at any age warrants professional evaluation. For young people diagnosed with breast cancer, asking about genetic testing for mutations such as PALB2 can inform treatment strategies and guide family members’ screening plans. If a concern is not taken seriously, it is reasonable to seek additional input, ask precise questions about what steps will definitively rule out cancer, and advocate for one’s own health. This story is sobering, but it is also a reminder of how attentive clinicians, persistent patients, and genetic insights can align to improve outcomes for individuals and families facing breast cancer at a young age.